Moreover, previous studies have shown that CSF p‐tau markers become abnormal prior to tau PET and may thus be more sensitive biomarkers for early AD (Mattsson et al, 2017; Meyer et al, 2020; Reimand et al, 2020b). This evidence concerns the gene MAPT and Alzheimer disease.